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Introduction: The eastern part of India has been affected by an ongoing low-intensity conflict between government
forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing
primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011,
treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe
MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a
low-intensity conflict setting in India.
Case description: A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January
2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB
clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the
MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines.
Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became
lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused
treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of
their intensive phase of treatment.
Discussion and evaluation: Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and
technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible
to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term
commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to
follow-up in patients remains a programmatic challenge and community involvement may play a key role.
Conclusion: Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an
appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered
to further simplify treatment delivery and allow for scale-up when needed.
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The conflict
The eastern part of India has been affected by an ongoing
low-intensity conflict between government forces and
armed Maoist groups, known as Naxalites [1]. The regions
primarily affected have heavily forested areas with
significant unexploited natural resources, which con-
tributes to an on-going armed power-struggle for access
to these resources and their economic potential [2]. From* Correspondence: msfocb-asia-epidemio@brussels.msf.org
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article, unless otherwise stated.2005, around 6220 people have been killed in this con-
flict covering 12 states of Eastern India, with one third
of these casualties in Chhattisgarh state alone [3]. The
on-going low intensity conflict coupled with the signi-
ficant displacement of the civilian population have
resulted in poor access to health services [4].The health
The limited security and almost non-functional healthcare
services in these conflict zones have hindered universal
coverage of all national health programmes including
tuberculosis (TB), and in particular drug-resistanttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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(MDR-TB) is estimated to account for 2.1% of new cases
and 15% of previously treated TB cases [5]. Reports from
several states suggest that the prevalence of DR-TB may
vary from 7% to over 50% [6-10]. The Revised National
Tuberculosis Control Programme (RNTCP) has helped to
enable MDR-TB patients access appropriate medication
through government nationwide health structures [11,12]
however, coverage in conflict zones remains a challenge.
In 2006, in response to the conflict and the resultant
significant civilian displacement to temporary relief camps
Médecins Sans Frontières (MSF) started a primary health
care mobile clinic service in the border area between the
states of Chhattisgarh and Andhra Pradesh. This conflict
may have contributed to the spread of DR-TB in the area
by disrupting health care services, inhibiting both access
of directly observed treatment (DOT) providers to their
patients and also patient’s access to health services, inter-
rupting drug supplies and the inevitable close habitation
of DR-TB patients in temporary housing due to forced dis-
placements. Thus, along with primary healthcare services,
the MSF programme provided treatment to patients suf-
fering from drug-sensitive TB and DR-TB.
Treatment of DR-TB is highly specialised, complex
and expensive, and needs appropriate tools to monitor
the long and painful regimen. Availability of these pre-
requisites for DR-TB treatment and care in remote rural
settings is uncertain. To date, little is known about DR-
TB management in a primary health care setting in areas
affected by conflict [13]. To address this knowledge gap,
this report aims to describe MSF experiences of provid-
ing treatment to DR-TB patients in a mobile primary
health care outpatient clinic, in a low-intensity conflict
setting in India. We describe the treatment model that
was followed in the MSF programme, particularly the use
of a nurse-aid-implemented, remote-expert-guided ap-
proach to management. To our knowledge, this is the first
report describing a treatment model providing DR-TB ser-
vices to patients in a conflict setting in India [14,15].
Case description
Setting and study population
Since 2006, MSF has been operational in the border
region between Andhra Pradesh and Chhattisgarh (AP-CG).
The project runs from the town of Bhadrachalam and
has sub-bases in the small border towns of Konta and
Cherla. The MSF mobile clinics provide care free of
charge to patients and can help to facilitate referral to
secondary care for patients requiring emergency care.
The great majority of patients are from rural forested
tribal areas often lacking in basic water or sanitation ser-
vices or access to functioning healthcare facilities. In
general, about one-third of patients attending the MSF
clinics walk more than 10 km to reach the clinic location.MSF started providing DR-TB treatment to patients from
January 2011. DR-TB care and treatment is offered in an
outpatient primary healthcare setting.
The study population consisted of all DR-TB patients
registered for care within the MSF programme between
January 2011 and October 2013.
Diagnostic and treatment model
All the patients presenting with presumed TB undergo
sputum smear evaluation [16] in the Bhadrachalam des-
ignated microscopy centre (DMC) in Andhra Pradesh.
A passive, facility-based case finding strategy is followed
to identify patients with presumed TB. After smear
evaluation, the following criteria are used to determine
which TB patients are most at risk of having DR-TB.
▪ Category 1 and Category 2 treatment failure
▪ All retreatment cases and all cases starting Category 2
treatment
▪ Close contacts of known DR-TB patients
▪ HIV-infected TB patients
Patients who fall into the above categories are pre-
sumed to have a higher likelihood of DR-TB and their
samples are then sent for sputum culture and drug sus-
ceptibility testing (DST). The following diagnostic and
treatment model is being used:
1) Sputum collection and transfer to specialist
laboratory for culture and Drug Susceptibility
Testing (CDST): Two sputum samples, usually a
spot and a morning sample, are collected and
transferred via courier to the MSF HIV MDR-TB
project in Mumbai, India. Delivery of these samples
takes 2 working days and the sample is delivered to
an RNTCP accredited private laboratory for culture
and DST. Information regarding the possible DR-TB
patient is made anonymous , entered into a database
and sent via email to the MSF Mumbai MDR-TB
technical referent. Since July 2013, the samples for
line probe assay (LPA) are sent to Hyderabad
RNTCP accredited laboratory, Andhra Pradesh.
2) A shared database (electronic- excel based) between
the project staff and Mumbai TB technical referent
is used to record the patients’ treatment progress.
The database specifically monitors patients’ follow
up sputum sample outcomes, blood test results and
adverse events.
3) Pre-treatment evaluation: Following confirmation of
a positive DR-TB result, a pre-treatment evaluation
is carried out including basic hematological and
biochemical investigations (including creatinine
clearance) and an HIV test. Adherence counseling
and health education sessions are given. A treatment
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treatment is received from all the patients.
4) Individualised treatment regimen: The treatment
protocols follow WHO guidelines [16]. However,
during the initial years of the project, other
international guidelines were followed [17].
Whenever possible, an individualized treatment
regimen is designed for each patient by remote
technical experts from the MSF Mumbai project.
The treatment regimen is based on the first and
second line DST results and on patients’ previous
treatment histories. All TB drugs are dosed
according to bodyweight. Dosing and drugs are also
changed in response to severe adverse effects.
Adverse events are aggressively managed and
regimen modification is done as last resort if
required. Medications are purchased and supplied by
the MSF Mumbai project.
5) Treatment initiation and follow up: After treatment
initiation, sputum smear and culture is repeated
monthly until the end of the intensive treatment
phase and every other month during the continuation
phase. Chest X-ray is not routinely used for treatment
monitoring. A directly-observed treatment (DOT)
approach is followed depending on the level of
insecurity in the area, using MSF community health
workers, Furthermore, an MSF nurse, nurse aid or
patient support officer would review the patient on
a weekly basis to confirm compliance and report
adverse events. If the patient remains stable, medical
reviews by the MSF doctor occurs on a monthly basis.
All treatment is provided free of charge. Additional
supportive counseling is provided to patients who
interrupt treatment. The tracing of lost-to-follow-up
patients is carried out by a local team of MSF health
workers.
Data collection and analysis
Demographic and clinical information were recorded in
patient files. The clinical data being routinely collected
for each patient, including treatment and laboratory
data, were entered into an electronic shared database.
Data from all TB patients initiated on treatment between
January 2011 and October 2013 were included in the
analysis.
Ethics
This case-study satisfied the criteria for reports using rou-
tinely collected programmatic data set by the Médecins
Sans Frontières Ethics Review Board (ERB), Geneva,
Switzerland. Patient identifying information was re-
moved prior to analysis. As this was a study of routinely
collected monitoring data, patient consent was not
required.Patient treatment outcomes
Between Jan 2011 and October 2013, 13 patients were
diagnosed with DR-TB (Table 1). The majority (80%) of
them were males. All except one of the patients were
adults. Six of the patients were from Andhra Pradesh
and seven were from Chhattisgarh. None of the patients
were found to be HIV-infected. All patients had pul-
monary DR-TB: four patients had mono-drug resistant,
four had poly-drug resistant and five had multidrug-
resistant tuberculosis.
Of the thirteen patients initiated on treatment, seven
patients completed treatment and were declared cured.
Three patients were on-treatment, clinically improving
and were culture-negative at the end of their intensive
phase. The treatment regimen and duration for each
patient is described in the table. One patient was lost to
follow-up prior treatment initiation, one refused treat-
ment and one died before starting treatment. In all,
seven (70%) of ten patients with treatment outcome
were cured. Adverse events were common (31%) among
this cohort of patients. Among them, a patient had base-
line renal dysfunction with a creatinine clearance of
21 ml/min, thus the treatment doses were adjusted in
line with published recommendations. Another patient
developed psychological disturbances after three months
of treatment and required referral to a psychiatrist. The
patients suffering from ototoxicity or gastrointestinal
disturbances were managed symptomatically.
Discussion and evaluation
Our experiences demonstrate that it is feasible to pro-
vide treatment to DR-TB patients within this particular
conflict setting. The MSF position as a neutral actor, has
allowed it to build trust and ensure continued access to
the people it treats, in this chronic low-intensity conflict
zone. On a day to day basis there is normally no immedi-
ate threat to the health workers which is vital for being
able to deliver DR-TB medication on a daily basis. The
patient cohort, rather than being direct victims of warfare
find themselves as indirect victims. They are affected by
intimidation, difficulties in travel and access to healthcare
services due to the background security situation, as
well as seasonal problems including monsoon rains and
flooding. Our study shows that despite these challenges
it is possible to deliver care and medications for the dur-
ation of the treatment period for DR-TB.
Our treatment model shows it is possible to manage
and follow-up DR-TB patients in a primary care setting
with non-specialists, rather than requiring a vertical DR-TB
programme, if there is a system in place for supportive
guidance from DR-TB experts, as previously documented
in other MSF programmes [13]. It may be possible to adopt
this approach in similar remote or conflict affected
areas. In addition, as the expert guidance is provided
Table 1 Clinical characteristics and treatment outcome details of pulmonary, drug-resistant TB patients in Chhattisgarh-Andhra Pradesh border, India
Case Age Sex State of origin AFB smear result Resistance profile DST TB Resistance pattern Treatment regimen Duration (months) Adverse events Outcome
1 50 M AP Pos S,H,Z PDR Inj Km/Mx/ R/E 14 Oto-toxicity Cured
2 40 F AP Neg H Mono-R Inj Km/Mx/ R/E/Z 14 - Cured
3 25 M AP Neg H,Z PDR - - - LTFU
4 45 M AP Pos S,H,R,Z,E MDR Inj Cm/Mx/ Eto/Cs/PAS 24 GI dista Cured
5 40 M CG Pos H Mono-R Inj Cm/Mx/ R/E/Z 12 Psychb Cured
6 45 M CG Pos S,H,R,Z MDR Inj Cm/Mx/ Eto/Cs/PAS 24 - Cured
7 45 M CG Pos S,H,Eto PDR Inj Cm/Mx/ R/E/Z 13 Renal dysc Cured
8 45 M CG Pos S,H PDR Inj Cm/Mx/ R/E/Z 13 - Cured
9 45 F CG Pos H,R MDR Inj Km/Lx/ Eto/Cs/E/Z 7 - On-treatment┼
10 13 F CG Pos H Mono-R H/R/Z/E 6 - On-treatment┼
11 35 M AP Neg H,R,Z MDR Inj Km/Lx/ Eto/Cs/E/Z 7 - On-treatment┼
12 25 M CG Pos H,R MDR - - - Died
13 60 M AP Pos H Mono-R - - - Refused treatment
M: Male, F: Female, AP: Andhra-Pradesh, CG: Chhattisgarh, Pos: Positive, Neg: Negative.
aGI dist: Gastro-intestinal disturbance, bPsych: Psychological complaints, cRenal dys : Renal dysfunction.
Mono-R: Mono-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to one first line anti-TB drug.
PDR: Poly-resistance tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant to more than one first line anti-TB drug, but not MDR-TB.
MDR: Multi-drug resistant tuberculosis; defined as drug-resistant TB case whose recovered M. tuberculosis isolate is resistant in-vitro to isoniazid and rifampicin with or without resistance to other anti-tubercular drugs
based on DST results.
S: Streptomycin, H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: Ethambutol, Eto: Ethionamide, Km: Kanamycin, Mx: Moxifloxacin, Cm: Capreomycin, Cs: Cycloserine, PAS: Para-amino salicylic acid, Lx: Levofloxacin.
LTFU: Lost to follow up.
┼Culture negative at end of intensive phase; currently in continuation phase.
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decentralised primary healthcare providers who would
use this same distance approach for the management of
their DR-TB patients.
Our DR-TB patient cohort included similar number of
patients from Chhattisgarh and Andhra Pradesh. This
accurately reflects the border locations of the MSF
clinics. About 23% (3/13) of the patients were women.
Further, 7.7% (1/13) patients were children (<16 years
old), which may reflect the ongoing challenges in diag-
nosing and managing children with TB [18]. However,
limited conclusions on epidemiological profile of DR-TB
patients may be drawn, due to the small size of the
cohort.
There is little published evidence of the non-governmental
organization (NGO) sector managing DR-TB in conflict
settings. There is justifiable concern regarding trying to
make a diagnosis if the expensive medications and any
follow up system is not in place or is unrealistic given the
context. Indeed, a sporadic or non-sustainable approach
to DR-TB management in conflict settings could do more
harm than good including leading to the amplification of
resistance. Previous studies from Peru [19] and Mumbai
[6] have demonstrated that it is possible to manage
DR-TB patients in an ambulatory way without the need
for in-patient services and this opportunity should be
considered by other actors considering DR-TB pro-
grammes in conflict or remote settings.
A limitation to our treatment model is the varied
treatment regimens used to treat our mono-resistant
and poly-resistant DR-TB cohort, which in the current
era may seem inappropriate. However, these regimens
were prepared based on available literature and inter-
national guidelines then [16,17]. The patients registered
for care more recently were provided treatment based
on new international [20] and national guidelines [21]
published in recent years.
A second limitation was the prolonged duration of
treatment for several of the patients. These were mostly
due to delays in receiving patient laboratory reports or
due to the patient’s severe or non-improving clinical
condition. Another reason behind prolonged treatment
was treatment interruptions by the patients. These pa-
tients missed appointments ranging from one week-one
month during their treatment duration. The MSF staff
had to trace back these patients by visiting their resi-
dence or sending confidential messages via residents
from the same villages.
A few months after the MSF project in AP-CG region
had been operational; the national TB programme
(RNTCP) acknowledged the DR-TB burden in India and
initiated the upscaling and investment in services for
DR-TB. This includes the investment in molecular resist-
ance testing including line probe assay (LPA) techniquesand the availability of free DR-TB medications through
the RNTCP. This enabled MSF to adapt its strategy in
2013 from one of being the provider of the entire DR-TB
package of care for its patients and thus requiring a
minimum commitment of two years in order to ensure
the availability of medication for the duration of treat-
ment and taking on more of a facilitator role. This has
meant that new suspected DR-TB patients attending the
MSF clinics may now have their diagnosis performed in
one of the RNTCP accredited laboratories, their medi-
cations provided by the national programme but their
clinical follow up and delivery of medications to the
patients still conducted by the MSF mobile clinic staff.
In this way, there is the reassurance that patients can in
future be handed over to the RNTCP programme
should the need arise albeit within the context of the
challenging security situation.
Due to sufficient resources and small patient numbers,
the DR-TB patients received an individualised treatment
regimen based on standard treatment guidelines [16,17]
suggested by remote technical experts from the MSF
Mumbai project. Whether this individualised approach
is necessary for other similar projects operating in
challenging contexts is questionable. If reliable DST
is available to second line TB medications then the patient
receive optimum treatment regimens however, in
scenarios where there is significant cost or delay to
achieving second line DST, or where patient numbers
are sufficiently high to make individualised regimens
too complex to manage, it may be appropriate to have
a standardised DR-TB regimen which is used for all
patients. We hypothesise that populations in contexts
similar to ours may have low exposure to second-line
TB medication, further justifying the need for standar-
dised regimen. Actors designing a DR-TB programme
should consider the local population resistance pat-
terns and the feasibility, benefits and limitations of
each option and take into account the scalability of
each approach.
One problem encountered is regarding the patients
who are lost to follow up either on a temporary basis or
permanent, as was the case for one study patient. Signifi-
cant difficulties exist regarding tracing patients who do
not attend appointments or who are not available when
their DOT provider goes to observe treatment. To try
and limit missed doses, attempts are made to communi-
cate in advance when patients needed to come to clinic,
including sending reminders through respected mem-
bers of the relevant villages. Furthermore, as a consider-
able number of patient villages are impossible to visit
due to limited security, patients are strongly encouraged
to come together with their close family members in order
to encourage family support of the patient, thereby im-
proving the adherence of the patients during treatment
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cooked meals for patients during each visit should be
explored to improve adherence.
Conclusions
The drug-resistant tuberculosis diagnosis and treatment
remains a highly specialised and technical subject which
requires continued patient follow-up. However, in areas
affected by low-intensity conflicts, our study has shown
that with an appropriate treatment model and remotely
given expert support, it is possible to implement a DR-TB
programme within a primary health care project. The
implementation of any such project requires a sustained
commitment and an understanding of the implementa-
tion challenges.
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